Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Acts centrally on the medullary cough centre, reducing the neural signals that trigger cough. It has opioid-related pharmacology but is used primarily as an antitussive rather than as an analgesic.
Indications / reported uses
Historically used for symptomatic treatment of non-productive (dry) cough in adults and children, including in combination cold-and-flu products.
Pholcodine-containing medicines were withdrawn from the EU market in 2023 because use in the preceding 12 months was associated with an increased risk of peri-anaesthetic anaphylaxis to neuromuscular blocking agents. Current availability and restrictions vary by jurisdiction.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Pholcodine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Pholcodine Permitted Daily Exposure (PDE) report (the Pholcodine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Pholcodine Occupational Exposure Limit (OEL) report (the Pholcodine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.